EMAIL THIS PAGE TO A FRIEND

British journal of clinical pharmacology

Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man.


PMID 2713216

Abstract

1. The interindividual differences in serum concentrations of dextromethorphan (DM) and its metabolites were studied in 29 healthy subjects given 120 mg orally. They were also phenotyped according to the urinary ratio of debrisoquine and 4-hydroxy-debrisoquine. 2. Four (14%) subjects were found to be poor metabolizers (PM) with a dextromethorphan/dextrorphan metabolite ratio in plasma of 3.6 or more compared with extensive metabolizers (EM) with a ratio of 0.11 or less. Significant levels of 3-hydroxymorphinan were measurable in all individuals except two, both of whom were PMs. This subdivision corresponded to the phenotype determined by the metabolic ratio of debrisoquine (r = 0.92). 3. Twelve of the 29 subjects reported adverse drug reactions after dextromethorphan administration compared with none after placebo.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

H156
(+)-3-Hydroxymorphinan hydrobromide, neurotrophic to dopaminergic neurons
C16H21NO · HBr